Symptoms improved significantly in adults with the bleeding disorder hemophilia B following a single treatment with gene therapy developed by researchers at St. Jude Children’s Research Hospital in Memphis and demonstrated to be safe in a clinical trial conducted at the University College London (UCL) in the U.K.
The findings of the six-person study mark the first proof that gene therapy can reduce disabling, painful bleeding episodes in patients with the inherited blood disorder. Results of the Phase I study appear in the December 10 online edition of the New England Journal of Medicine. The research is also scheduled to be presented December 11 at the 53rd annual meeting of the American Society of Hematology in San Diego.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46766-st-jude-children-s-research-hospital-gene-therapy-bleeding-disorder
The Leukemia & Lymphoma Society (LLS) today announced it has committed $40.3 million in new research investments to advance the most promising blood cancer science at leading academic and medical centers around the world, including Dana-Farber Cancer Institute in Boston; Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center in New York; MD Anderson Cancer Center in Houston; Fondazione Centro San Raffaele in Milan; and South Australian Health & Medical Research Institute in Adelaide.
This $40.3 million investment, comprised of 75 new research grants in LLS’s portfolio of 300 projects, will fund a diverse array of research to find better treatments and cures for patients with leukemia, lymphoma, myeloma and other blood cancers.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554855-lls-invests-millions-new-research-treatment-cures/
http://www.ftrintl.com/ FTR International Inc. is a an award-winning and highly innovative Union general contracting, engineering, and construction management firm that has successively proven its exceptional ethic in the successful delivery of over 100 multi-million dollar projects since our initiation in 1984. With offices in Irvine and Los Angeles, California, FTR prides itself with a diverse public works and private project portfolio, totaling billions of dollars' worth of construction costs in General Contracting, Design/Build and Construction Management delivery. Our diverse project portfolio includes state-of-the-art science laboratories, health centers, educational institutions, aviation terminals, art and theater facilities, ultra-modern mass transit stations, port security services, complex water reclamations, environmental sewage treatment facilities, and electrical power distribution centers and our industry reach extends to more than sixty public agencies.
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Eighteen years after opening its internationally prominent Center for Fetal Diagnosis and Treatment, The Children’s Hospital of Philadelphia (CHOP) celebrates 1,000 fetal surgeries – highly complex surgical interventions to repair birth defects in the womb. Approximately 4,000 fetal surgeries have been done worldwide, meaning a quarter of them have been performed at CHOP, the largest number of any hospital in the world.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/62038-children-s-hospital-of-philadelphia-celebrates-1000-fetal-surgeries
https://www.FertilityFactor5.com/ct/8... Fertility Factor 5: Male Infertility? Here’s A New Male Fertility Supplement
Now, there is finally, an all-natural, way to improve male fertility. If you are trying to conceive but you have sperm with low count, poor shape or bad motility, here is a new product that can help you with these issues.
1 in 3 women will notice hair thinning in her lifetime, and it can start as early as her 20’s. Today, the hair regrowth category leader, ROGAINE® Brand, announced the official launch to market of Women's ROGAINE® 5% Minoxidil Topical Aerosol, the first and only FDA-approved, once-daily use treatment for Female Pattern Hair Loss containing 5 percent minoxidil in an elegant foam formula. Minoxidil is the only topical ingredient FDA-approved to help regrow hair.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7368851-introducing-women-s-rogaine-5-percent-minoxidil-topical-aerosol-fda-approved/
Inspire Medical Systems, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Inspire Upper Airway Stimulation (UAS) therapy for use in a subset of patients with moderate to severe Obstructive Sleep Apnea (OSA) who are unable to use Continuous Positive Airway Pressure (CPAP). Inspire therapy is a fully implanted neurostimulation device, the first of its kind for sleep apnea, that provides an alternative treatment that is proven, convenient and easy to use.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7169651-fda-approves-inspire-upper-airway-stimulation-therapy-sleep-apnea
Thirty-six million Americans suffer from migraines, leading to more than $20 billion in medical expenses and costs related to lost productivity each year¹. In recognition of National Migraine Awareness Month and the significant unmet medical needs of migraine patients, Zogenix, Inc. (NASDAQ: ZGNX) is highlighting the importance of selecting the appropriate medication for a patient’s “treatment toolbox” to address specific types of migraine episodes.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/zogenix/50344/
The American Society for Aesthetic Plastic Surgery (ASAPS), is hosting a panel discussion about the latest best practices and uses for injectables including the newest FDA-approved options at The Aesthetic Meeting today in Montreal, Quebec Canada.
The panel discussed the latest advances, including the ways various dermal fillers can be utilized to produce optimal results for targeted areas. There are thirteen FDA-approved dermal fillers on the market to-date, providing aesthetic plastic surgeons with the ability to customize anti-aging treatments to patients’ needs. “The filler choices are dictated by a patient’s unique aging pattern, the anatomical area to be treated and physiochemical properties,” explains ASAPS member, Dr. Z. Paul Lorenc.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7310753-asaps-facial-rejuvenation-injectables/
“Explore Your Treatment Options,” a new multimedia ad campaign announced today by the U.S. Department of Health and Human Services’ Agency for Healthcare Research and Quality (AHRQ) and the Ad Council, encourages patients to become more informed about their options before choosing a treatment for a health condition or illness.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/adcouncil/50583/
